In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback